Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

sure it does. Look at the 2 positive results we got for phase 1a and phase 1b. Both good results yet we got shorted completely. The OTC has too much manipulation in it. Many companies are suffering the same fate in the OTC>

As for benefit? Basically now all institutions can invest in RXII now. Where as before none could. That's a huge benefit. This means also when we get news we won't be shorted entirely.

If you go back to phase 1 single dose results we got good results, but 50% of the 2 mil volume we got that day was shorted. Too much manipulation on the OTC so I think the uplisting is the best scenario possible for RXII.